


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (Canceled).

9. (Previously presented): A compound of formula (I):



(I)

wherein:

R^1 represents -C₁₋₆ alkyl substituted by 1, 2, or 3 halogen or cyano groups; -C₀₋₄ alkyl-C₃₋₈cycloalkyl; -C₂₋₄ alkyl-oxy-C₁₋₄ alkyl; -C₁₋₄ alkyl-aryl, wherein said cycloalkyl or aryl groups of R^1 may be optionally substituted by 1, 2, or 3 groups selected from halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino and trifluoromethyl;

R^2 represents hydrogen or C₁₋₆ alkyl;

m represents 1;

R^3 represents hydrogen, methyl or halogen;

R^4 and R^5 independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

A represents phenyl optionally substituted by a halogen, cyano, trifluoromethyl, or trifluoromethoxy group;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (Previously presented): The compound according to claim 9, wherein: A is unsubstituted phenyl.

11. (Previously presented): A compound which is:

8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

12. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.

13. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 11 and a pharmaceutically acceptable carrier or excipient.

14. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

15. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 11 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

16. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

17. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

18. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

19. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

20. (Currently amended): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

21. (Previously presented): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.